爱尔兰医疗体系无法以现时价格买得起Mounjaro, 需要73%的削减才能生存。 Ireland's healthcare system can't afford Mounjaro at current prices, needing a 73% cut to be viable.

一项新的研究发现,爱尔兰的公共保健系统无法按其目前价格(每年每名病人5,526欧元至6,214欧元)买得起减重药物Mounjaro。 A new study finds Ireland's public healthcare system cannot afford the weight-loss drug Mounjaro at its current price, which ranges from €5,526 to €6,214 annually per patient. 国家药物经济学中心建议对5毫克剂量实行73%的价格削减,使其具有成本效益,警告五年预算影响可能达到52亿欧元。 The National Centre for Pharmacoeconomics recommends a 73% price cut for the 5 mg dose to make it cost-effective, warning the five-year budget impact could reach €5.2 billion. Mounjaro比目前可用的Saxenda更有效、更方便使用,只有私人病人每月能使用140欧元280欧元。 Mounjaro, more effective and easier to use than the currently available Saxenda, is only accessible to private patients at €140–€280 monthly. 由于对承受能力的关切,公共资金仍然有限,专家们指出,甚至30%至40%的价格降低也不可能解决长期的可持续性问题。 Public funding remains limited due to affordability concerns, with experts noting that even 30–40% price reductions may not resolve long-term sustainability issues.